SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

AbbVie buys Pharmacyclics, bags Imbruvica blood cancer blockbuster

05-Mar-2015 - AbbVie is set to buy Californian small-molecule maker Pharmacyclics for $21bn (€19bn), cementing its haematology-oncology business.

Sun Pharma goes after opiates with deal to buy GSK’s Aus business

03-Mar-2015 - Indian giant Sun Pharma has bought GSK’s Australian Opiates business.

FTC requires Novartis to divest two potential cancer drugs to Array as part of GSK deal

24-Feb-2015 - In order to close Novartis’ $16bn purchase of GlaxoSmithKline’s portfolio of cancer treatments , the FTC (Federal Trade Commission) is requiring Novartis to divest all assets related to its potential BRAF and...

AMRI looks to close API facility in Wales as part of network realignment

12-Feb-2015 - AMRI has announced plans to close an API development and manufacturing plant in Wales, UK, after efforts to establish it as a conduit between the US and Europe were deemed...

Dispatches from BIO CEO 2015

Pfizer CEO slams US tax code, calls for more industry consolidation

11-Feb-2015 - In a wide-ranging interview that included his take on competition from Google and R&D spending, Pfizer CEO Ian Read offered a number of clues as to where his company is...

Pfizer 'comfortable' with Hospira's manufacturing network after quality review

09-Feb-2015 - Pfizer visited three troubled facilities in Hospira’s manufacturing network before entering a $17bn definitive merger agreement, the company says.

Vertellus buys antiretroviral API reagent plant from Dow

04-Feb-2015 - Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a Dow plant in Washington State.

UPDATE

Novartis: New cost-saving unit will not target manufacturing network

29-Jan-2015 - Novartis has divested, restructured, or mothballed 24 manufacturing plants since 2010 but says its new NBS cost-saving business will not focus on streamlining and consolidating sites.

Shire takes $5bn gamble on NPS' hormone replacement PDUFA decision

12-Jan-2015 - Shire says its $5.2bn (€4.4bn) acquisition of NPS Pharmaceuticals is a calculated risk, coming just days before the US FDA decides whther to approve the hormone replacement therapy Natpara.

Sosei looks to $23bn peptide market with acquisition of tech firm Jitsubo

15-Dec-2014 - Sosei Group Corporation is looking to peptides to replenish its pipeline through the $70m acquisition of technology firm Jitsubo.

Sun closes in on Ranbaxy deal with CCI approval

10-Dec-2014 - The Competition Commission of India (CCI) has approved Sun Pharma’s $3.2bn acquisition of Ranbaxy.

Happy Thanksgiving for GSK with FTC approval of Novartis vaccine biz

27-Nov-2014 - Just in time for the holidays, GSK can ‘give thanks’ to the US Federal Trade Commission (FTC) which has approved the $7bn acquisition of Novartis’ vaccine business.

Johnson Matthey: APIs down but Sigma-Aldrich acq could bring opportunities

24-Nov-2014 - The acquisition of Sigma-Aldrich by Merck KGaA could provide some opportunities for Johnson Matthey, the fine chemical company says as it reports a flat first half 2014/15.

BASF sells Norway plant, focuses on pharma grade omega-3 products

24-Nov-2014 - BASF says the supply of API to GSK and other pharma customers will not be affected by the divestment of an omega-3 production plant in Norway.

Actavis to acquire Botox maker Allergan for $66bn

17-Nov-2014 - After fending off hostile takeover bids from Valeant for nearly seven months, Allergan is finally agreeing to a takeover, but with Ireland-based Actavis.

Actavis takes axe to Forest again, with New York jobs to go

23-Oct-2014 - Almost 100 jobs at a commercial packaging facility in New York are set to go as part of Actavis’s continued integration of Forest Laboratories.

Strides Arcolab to leverage API business in Shasun acquisition

01-Oct-2014 - The acquisition of Shasun Pharmaceuticals will add API production and contracting services to Strides Arcolab, and according to Shasun’s CEO no jobs will be lost.

Acorda gains pulmonary drug delivery tech in $525 Civitas deal

25-Sep-2014 - Acorda has gained a pulmonary delivery technology and a GMP manufacturing site in Massachusetts along with a Parkinson’s disease candidate in its $525m (€410m) acquisition of Civitas.

Breaking news

Merck KGaA: $17bn 'Rolls Royce' Sigma-Aldrich to keep major St Louis site

22-Sep-2014 - The $17bn (€13.2bn) acquisition of Sigma-Aldrich is “not just a milestone but a quantum leap” for Merck KGaA, the firm says.

$20m Andromeda strains Hyperion as fake data ends diabetes drug development

09-Sep-2014 - Hyperion says it is “shocked and disheartened” after discovering Phase III trial data for a type 1 diabetes candidate was manipulated by employees of recently acquired Andromeda Biotech.

INFOGRAPHIC

Is Pfizer now eyeing up Actavis three months after failed AZ bid?

28-Aug-2014 - Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a $120bn megamerger, but what would such a deal bring to the Pharma Giant?...

Catalent contract secure as Roche buys InterMune for $8.3bn

25-Aug-2014 - Roche has bought InterMune for $8.3bn (€6.3bn) and says it will continue contracts with Catalent and two API suppliers for the manufacture of its lead product Esbriet (pirfenidone).

Actavis welcomes AZ in boosting its LAMA/LABA

06-Aug-2014 - Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.

AstraZeneca coughs up $875m for Almirall to support asthma/COPD pipeline

04-Aug-2014 - AstraZeneca has bolstered its respiratory portfolio and added new bronchodilator technologies through the $875m (€650m) acquisition of Almirall.

Anti-addiction film resilient to generics, says Reckitt Benckiser

29-Jul-2014 - Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business....